Lixte Biotechnology, Inc.
Records under this name other than the patents Lixte Biotechnology, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 22 patents it holds.
Showing 1 to 7 of 7 · Back to Lixte Biotechnology, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,434,100 | Protein Phosphatase 2A Inhibitors for Treating Myelodysplastic Syndromes Formerly held In force · High confidence | In force | High confidence | |
| US 10,071,094 | Protein Phosphatase 2A Inhibitors for Treating Myelodysplastic Syndromes Formerly held Lapsed on the fee record Ended Sep 11, 2026 · Medium confidence | Lapsed on the fee record | Ended Sep 11, 2026 | Medium confidence |
| US 9,833,450 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders Lapsed on the fee record Ended Dec 5, 2025 · From the USPTO record | Lapsed on the fee record | Ended Dec 5, 2025 | From the USPTO record |
| US 8,541,458 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use Lapsed on the fee record Ended Sep 24, 2025 · From the USPTO record | Lapsed on the fee record | Ended Sep 24, 2025 | From the USPTO record |
| US 8,455,688 | HDAC inhibitors Lapsed on the fee record Ended Jun 4, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 4, 2025 | From the USPTO record |
| US 8,329,719 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases Lapsed on the fee record Ended Dec 11, 2024 · From the USPTO record | Lapsed on the fee record | Ended Dec 11, 2024 | From the USPTO record |
| US 9,526,915 | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase Lapsed on the fee record Ended Dec 27, 2020 · From the USPTO record | Lapsed on the fee record | Ended Dec 27, 2020 | From the USPTO record |